Joshua Levine
Chief Executive Officer
Executive Management
XTL BiopharmaceuticalsÂ
Israel
Biography
Joshua Levine was appointed Chief Executive Officer of XTL in October 2013. From January 2011 until September 2013 Josh served as the Chief Executive Officer of Proteologics (TASE: PRTL). From September 2008 until September 2010, he was Chairman of the Board of Proteologics Ltd. Concurrently, he was Senior Director at Teva Innovative Ventures responsible for, among other things, business development as well as alliance management for the unit. He has also held several executive positions within venture capital funds and boutique investment banks. Previously, he was a corporate attorney at a large New York City law firm. Mr. Levine holds a JD degree from Columbia University Law School and a BA degree in Chemistry from Yeshiva University.
Research Interest
R & D
